Gonadotropin-Releasing Hormone
"Gonadotropin-Releasing Hormone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
| Descriptor ID |
D007987
|
| MeSH Number(s) |
D06.472.699.327.740.320 D12.644.400.400.740.320 D12.644.456.460 D12.644.548.365.740.320 D12.776.631.650.405.740.320
|
| Concept/Terms |
Gonadotropin-Releasing Hormone- Gonadotropin-Releasing Hormone
- Gonadotropin Releasing Hormone
- Gn-RH
- Gonadoliberin
- LHFSH Releasing Hormone
- Releasing Hormone, LHFSH
- LH-RH
- LFRH
- LH-Releasing Hormone
- LH Releasing Hormone
- LH-FSH Releasing Hormone
- LH FSH Releasing Hormone
- LHFSHRH
- LHRH
- Luliberin
- Gonadorelin
- Luteinizing Hormone-Releasing Hormone
- Luteinizing Hormone Releasing Hormone
- FSH-Releasing Hormone
- FSH Releasing Hormone
- GnRH
|
Below are MeSH descriptors whose meaning is more general than "Gonadotropin-Releasing Hormone".
Below are MeSH descriptors whose meaning is more specific than "Gonadotropin-Releasing Hormone".
This graph shows the total number of publications written about "Gonadotropin-Releasing Hormone" by people in this website by year, and whether "Gonadotropin-Releasing Hormone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 1 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 3 | 0 | 3 |
| 2009 | 3 | 2 | 5 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 3 | 1 | 4 |
| 2013 | 0 | 4 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 6 | 1 | 7 |
| 2017 | 0 | 4 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 6 | 1 | 7 |
| 2020 | 5 | 2 | 7 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 1 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gonadotropin-Releasing Hormone" by people in Profiles.
-
Shore ND, Morgans AK, Tutrone RF. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(39):3179-3182.
-
Shore ND, Cookson MS, Efstathiou E. The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(40):3351-3354.
-
Sannala CKR, MacLean C, Larsen F, van Os S, Jadhav P, Shore N, Morgans AK, Okwuosa T, Gobburu J. A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk. Clin Pharmacol Drug Dev. 2024 08; 13(8):915-929.
-
Klein KO, Vargas Trujillo M, Dragnic S, Van Komen S, Li M, Lee PA. Timing of onset of menses after GnRH agonist treatment for central precocious puberty. J Pediatr Endocrinol Metab. 2024 May 27; 37(5):451-461.
-
Shore ND, Mehlhaff BA, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Saad F. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer. Adv Ther. 2023 11; 40(11):4919-4927.
-
Amin M, Horst N, Gragnoli C. Linkage and association of variants in the dopamine receptor 2 gene (DRD2) with polycystic ovary syndrome. J Ovarian Res. 2023 Aug 10; 16(1):158.
-
Trujillo MV, Lee PA, Reifschneider K, Backeljauw PF, Dragnic S, Van Komen S, Yu J, Klein KO. Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty. J Pediatr Endocrinol Metab. 2023 Mar 28; 36(3):299-308.
-
Briscoe A, Chen K, Klein KO. No pubertal growth spurt, rapid bone maturation, and menarche post GnRHa treatment in girls with precocious puberty. J Pediatr Endocrinol Metab. 2022 Nov 25; 35(11):1401-1409.
-
Merkison J, Malcom C, Decherney A. Use of gonadotropin-releasing hormone (GnRH) agonist trigger in fertility preservation for patients with inherited genetic disorders. Front Endocrinol (Lausanne). 2022; 13:826419.
-
Shoemaker LN, Haigh KM, Kuczmarski AV, McGinty SJ, Welti LM, Hobson JC, Edwards DG, Feinberg RF, Wenner MM. ETB receptor-mediated vasodilation is regulated by estradiol in young women. Am J Physiol Heart Circ Physiol. 2021 09 01; 321(3):H592-H598.